What Is Mild Pulmonary Hypertension and Why It Matters

Mild pulmonary hypertension refers to a modest but measurable increase in blood pressure inside the arteries that connect your heart to your lungs. Until recently, many doctors considered pressures in this range too low to worry about, but research over the past decade has upended that view. A large meta-analysis found that people whose mean pulmonary artery pressure sat between 19 and 24 mmHg had a clearly higher risk of dying than those with normal pressures, and international guidelines responded by lowering the diagnostic threshold to capture these patients earlier.¹ Understanding what this diagnosis means, how it is detected, and what drives it can make a real difference in how you and your medical team respond.

How the Definition Changed

For decades, pulmonary hypertension (PH) was defined as a mean pulmonary artery pressure (mPAP) of 25 mmHg or higher, measured by threading a catheter into the right side of the heart. That cutoff was somewhat arbitrary, chosen at a 1973 conference and never rigorously validated. In 2018 and then again in 2022, major cardiology and respiratory societies dropped the threshold to above 20 mmHg, based on accumulating evidence that pressures in the low-20s already carry worse outcomes.² Alongside this change, a measure called pulmonary vascular resistance (PVR), which reflects how much the small blood vessels in the lungs resist blood flow, was also tightened. The new cutoff uses PVR above 2 Wood units, down from the older threshold of 3.³

The practical effect is that a group of patients who used to be told their pressures were “borderline” or “nothing to worry about” now formally have a diagnosis. The rationale is straightforward: if mild elevations predict worse health outcomes and earlier detection leads to better management, waiting until pressures climb higher costs lives. A large Veterans Affairs study of more than 21,000 patients showed that the risk of death started climbing at an mPAP as low as 19 mmHg and was significantly elevated in the 19-to-24 range compared to patients with pressures of 18 or below.⁴

Why Even Mildly Elevated Pressures Carry Risk

The concern with mild PH is twofold: it independently predicts worse survival, and it raises the odds that pressures will keep climbing. A UK study that applied the newer 2022 guidelines found that patients with an mPAP of 21 to 24 mmHg had roughly a 36% higher hazard of death compared with those whose pressures were normal, even after accounting for coexisting heart and lung disease.⁵ That risk wasn’t fully explained by the underlying conditions driving the pressure up. The mildly elevated pressure itself seemed to be part of the problem.

On top of the survival signal, people with mildly elevated pressures are more likely to progress to full-blown PH over time. A meta-analysis pooling data from studies that repeated catheterizations found that those starting in the mildly elevated range had roughly double the risk of crossing into established PH compared with people who started normal.⁶ Not everyone progresses, and the speed varies considerably depending on the underlying cause. For instance, patients with chronic thromboembolic disease and only mild pressure elevations showed no major deterioration on follow-up testing over three years in one study, suggesting that certain causes may be more stable than others.⁷ Still, the overall trend is clear enough that clinicians now treat mild PH as a warning sign rather than a benign curiosity.

What Causes Mild Pulmonary Hypertension

Pulmonary hypertension has dozens of potential causes, and the mild form is no exception. The most common driver, by a wide margin, is left-sided heart disease. When the left side of your heart struggles to pump efficiently or relaxes stiffly between beats, blood backs up into the lungs and raises pressure there. Heart failure with preserved ejection fraction, the type where the heart squeezes normally but fills poorly, is an increasingly recognized source of PH.⁸ Because this form of heart failure is common in older adults, mild PH tied to it often surfaces on echocardiograms done for other reasons.

Chronic lung diseases rank as the second most frequent cause. COPD is far and away the biggest contributor simply because so many people have it. In most COPD patients, the pressure elevation stays in the mild-to-moderate range, with mPAP often hovering between 20 and 25 mmHg, though it can spike higher during flare-ups, exercise, or sleep.⁹ Interstitial lung diseases, a group of conditions that scar the lung tissue, also commonly produce mild PH and carry an added hit to survival when they do.¹⁰

Autoimmune connective tissue diseases round out the major contributors. Systemic sclerosis (scleroderma) deserves special mention because PH develops in a significant fraction of patients, and screening programs have shown that most newly diagnosed cases start as mild disease. A large French multicenter screening study found newly diagnosed cases averaging an mPAP of about 30 mmHg, with the majority still in early functional classes.¹¹ A separate international study confirmed that roughly two-thirds of scleroderma patients with confirmed PH were still in mild functional categories at diagnosis.¹² Catching the disease at this stage is precisely why routine screening in scleroderma patients is now recommended.

Pre-Capillary Versus Post-Capillary Pressure

When a clinician sees elevated pulmonary pressure, the first question is where the problem originates. This distinction matters because it changes everything about treatment. In pre-capillary PH, the problem sits in the pulmonary arteries themselves: the vessels have narrowed, stiffened, or become blocked, and blood has difficulty getting through the lungs. In post-capillary PH, the problem is downstream. Pressure from the left heart backs up into the lungs, and the pulmonary vessels themselves may initially be normal.

The hemodynamic signature of post-capillary PH includes an mPAP above 20 mmHg alongside an elevated wedge pressure (above 15 mmHg), reflecting the left-heart backup.¹³ The reason this distinction is so important at the mild end of the spectrum is that post-capillary PH caused by left heart disease is far more common than the pre-capillary forms, and treating it with drugs designed for pulmonary arterial hypertension can actually make things worse by flooding a heart that already can’t keep up. Conversely, missing a pre-capillary cause in someone with mild pressures means losing the chance to start disease-specific therapy early.

A catheterization settles this question definitively, but researchers have also explored noninvasive ways to distinguish the two. One approach uses a simple ratio derived from echocardiography that compares a measure of right-heart pressure to a measure of left-heart filling pressure. In validation studies, pre-capillary patients had significantly higher values on this ratio than post-capillary patients, offering a way to triage patients before committing to an invasive procedure.¹⁴

The Accuracy Problem with Echocardiography

Most people first learn they might have PH from an echocardiogram, a painless ultrasound of the heart. It is cheap, widely available, and does not require a catheter. The trouble is that at the mild end of the pressure range, echocardiography is not especially accurate. A systematic review found that the correlation between echo-estimated pressures and catheter-measured pressures was moderate, with an overall sensitivity of about 83% and a specificity of roughly 72%.¹⁵ Those numbers look reasonable on paper, but the individual-level scatter is large.

One head-to-head comparison found that while the average pressures measured by echo and catheter were nearly identical across the group, the range of disagreement for any given patient was enormous, spanning roughly plus or minus 19 mmHg.¹⁶ For someone whose true pressure is 22 mmHg, the echo could plausibly read anywhere from the low single digits to the low 40s. A study in lung transplant candidates confirmed this pattern: echo overestimated pressures by more than 10 mmHg in about 35% of patients and underestimated them in about 12%.¹⁷

What this means in practice: if your echo report says “mild pulmonary hypertension,” that finding should be taken seriously as a reason to investigate further, but it is not the final word. Depending on the clinical situation, your doctor may recommend a right heart catheterization to pin down the actual number and, just as critically, to figure out whether the pressure is pre-capillary or post-capillary. At the same time, a normal echo does not guarantee your pressures are fine, because echo can also miss mild elevations entirely.

When Pressures Rise Only During Exercise

Some people have completely normal pulmonary pressures at rest but develop abnormal elevations when they exert themselves. This condition, known as exercise-induced pulmonary hypertension, sits in a diagnostic gray zone that has historically been controversial. It was dropped from official guidelines for years, partly because exercise normally raises pulmonary pressures to some degree and a clear cutoff was hard to define. More recently, a working definition has gained traction: an mPAP above 30 mmHg at a cardiac output below 10 liters per minute during exercise, combined with elevated resistance.¹⁸

Why does this matter for someone told they have “mild” PH? Because exercise-induced PH can be an early stage of the same disease. It has been reported in people with scleroderma, chronic lung disease, blood clots in the lungs, and even in carriers of certain genetic mutations linked to pulmonary arterial hypertension. In a proportion of these patients, pressures eventually become elevated at rest too.¹⁹ Abnormal pressure responses during exercise also predict reduced exercise capacity and higher mortality on their own, even before resting pressures become abnormal.²⁰ If you are short of breath with exertion but your resting echo looks normal, exercise testing may be the only way to catch the problem.

The Role of Sleep Apnea

Obstructive sleep apnea (OSA) has long been assumed to cause pulmonary hypertension through repeated drops in oxygen during sleep, but the relationship is more complicated than it first appears. About one in five patients with OSA has mild PH, with pressures elevated enough to be clinically meaningful.²¹ In that study, nearly half the OSA patients with mild PH also had elevated wedge pressures, pointing to left-heart involvement rather than a purely vascular problem. The strongest predictors of higher pulmonary pressure were left-heart filling pressure and the percentage of sleep time spent with oxygen levels below 90%.

The twist is that newer research suggests intermittent oxygen dips and apnea events alone do not correlate as strongly with pulmonary pressure as you might expect. Coexisting obesity, left-heart dysfunction, and daytime low oxygen levels likely play bigger roles in many patients.²² For someone with OSA who is told they have mild PH, the takeaway is that treating the sleep apnea alone may not be enough. A broader look at heart function, weight, and daytime oxygenation often reveals the true driver.

What Happens to the Right Side of the Heart

Your right ventricle is a relatively thin-walled chamber designed to pump blood through the low-resistance pulmonary circuit. When resistance rises even modestly, the right ventricle has to work harder. Over time, it can thicken, stiffen, and eventually fail. The question with mild PH is whether pressures in the low-20s are enough to start damaging this chamber.

The answer, based on imaging studies, is that the right ventricle does begin to show strain even at mildly elevated pressures, though the degree varies. Researchers have explored the ratio between right ventricular strain (how much the muscle deforms with each heartbeat) and the pressure it is pumping against. When strain drops relative to rising pressure, it suggests the ventricle is losing its ability to keep up. This coupling measure has shown prognostic value in pulmonary arterial hypertension, predicting who deteriorates and who remains stable.²³ In mild disease, the right ventricle is typically still compensating, meaning it has thickened enough to maintain output. The worry is that this compensatory phase does not last indefinitely, and the window for intervention is widest while the right ventricle is still coping.

Living at High Altitude

Altitude is a cause of PH that stands apart from heart or lung disease. At elevations above about 2,500 meters, the air contains less oxygen, and the pulmonary arteries constrict in response. For most visitors, this produces a small, temporary rise in pressure that resolves on descent. For people who live permanently at high altitude, the constriction can become chronic and the vessel walls can remodel, producing sustained PH. The development of high-altitude PH involves a web of processes including inflammation, oxidative stress, and changes in gene regulation that operate over months to years.²⁴

High-altitude PH is typically mild to moderate in severity and often undiagnosed because the symptoms, mostly breathlessness and fatigue, are easily attributed to the altitude itself. For populations living in the Andes, the Tibetan Plateau, or other high-elevation regions, this represents a widespread but underappreciated health burden. The practical relevance for lower-altitude readers is that relocating to or spending extended periods at high altitude can tip someone with borderline pressures into the mildly elevated range, especially if they already have an underlying lung or heart condition.

Symptoms That Are Easy to Dismiss

Mild PH is often called a “silent” condition because the symptoms are vague and overlap with everyday complaints. Breathlessness during routine activities is the most common, followed by fatigue, lightheadedness, and sometimes a sense that exercise tolerance has gradually declined. These symptoms creep in slowly, and many people unconsciously adjust by doing less, which masks the problem further.

Research on quality of life in pulmonary arterial hypertension patients shows that even at relatively low levels of breathlessness, physical quality-of-life scores drop well below average. The connection between worsening breathlessness and declining physical function is strong and graded: the more breathless you are, the worse you feel physically. Perhaps less obviously, breathlessness also correlates with poorer mental health and higher rates of depressive symptoms, though the mental-health link is weaker than the physical one. Delay in diagnosis of PH is well documented and linked to worse outcomes, and part of the reason for that delay is exactly this: the early symptoms do not scream “heart and lung disease.”³

Searching for Earlier Detection

Because catheterization is invasive and echocardiography is imprecise at the mild end, there is an active push to find blood-based or imaging-based tools that could flag PH earlier. One ambitious effort, the CIPHER study, tried to develop a blood test using tiny molecules called microRNAs that circulate in the bloodstream and change in PH. The signature showed decent sensitivity, correctly identifying about 85% of PH cases, but its specificity was poor. It flagged far too many people as positive who did not actually have PH, which limited its usefulness as a screening tool.²⁵ Adding a more established blood marker called NT-proBNP to the model improved sensitivity slightly but did not fix the specificity problem.

The search continues, but for now the realistic path to early detection relies on clinical suspicion: knowing which patients are at risk (people with scleroderma, chronic lung disease, left-heart disease, family history of pulmonary arterial hypertension, or unexplained breathlessness), screening them with echo, and following up with catheterization when the picture is ambiguous. It is an imperfect system, but the lowered diagnostic threshold means that the patients who do get catheterized are more likely to be caught before pressures have climbed to the point where treatment options narrow and the right ventricle has already been damaged.